Rivaroxaban

Generic Name
Rivaroxaban
Brand Names
Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
Drug Type
Small Molecule
Chemical Formula
C19H18ClN3O5S
CAS Number
366789-02-8
Unique Ingredient Identifier
9NDF7JZ4M3
Background

Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, ...

Indication

Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurre...

Associated Conditions
Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
Associated Therapies
-
Clinical Trials
Related News

Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2)

First Posted Date
2012-10-17
Last Posted Date
2016-09-08
Lead Sponsor
London Health Sciences Centre
Target Recruit Count
70
Registration Number
NCT01708850
Locations
🇨🇦

London Health Sciences Centre, London, Ontario, Canada

Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events

Phase 3
Completed
Conditions
Hematoma
Interventions
Drug: Dabigatran
Drug: Rivaroxaban
Drug: Apixaban
First Posted Date
2012-08-29
Last Posted Date
2019-10-07
Lead Sponsor
Ottawa Heart Institute Research Corporation
Target Recruit Count
663
Registration Number
NCT01675076
Locations
🇨🇦

Victoria Cardiac Arrhythmia Trials Inc., Victoria, British Columbia, Canada

🇨🇦

University of Alberta-ECAT Group, Edmonton, Alberta, Canada

🇨🇦

Hamilton Health Sciences General Campus, Hamilton, Ontario, Canada

and more 12 locations

Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy

First Posted Date
2012-06-27
Last Posted Date
2021-05-21
Lead Sponsor
University of Padova
Target Recruit Count
500
Registration Number
NCT01629381
Locations
🇮🇹

Department of Internal Medicine, Hospital of Piacenza, Piacenza, Italy

🇮🇹

Thrombosis Center & Knee Arthroscopy and Sports Medicine Center, Humanitas Clinical Insitute, Rozzano, Milano, Italy

🇮🇹

Department of Orthopaedics and Traumatology, University Hospital "Galliera" of Genova, Genova, Italy

and more 6 locations

Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia

Phase 3
Terminated
Conditions
Heparin-induced Thrombocytopenia
Interventions
Drug: Rivaroxaban
First Posted Date
2012-05-15
Last Posted Date
2016-03-25
Lead Sponsor
McMaster University
Target Recruit Count
22
Registration Number
NCT01598168
Locations
🇨🇦

Hamilton Health Sciences - Juravinski Site, Hamilton, Ontario, Canada

Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

First Posted Date
2011-12-26
Last Posted Date
2023-05-15
Lead Sponsor
GWT-TUD GmbH
Target Recruit Count
472
Registration Number
NCT01499953
Locations
🇩🇪

Universitätsklinikum Dresden, Dresden, Sachsen, Germany

🇩🇪

MVZ Ramdohr, Praxis für Cardiovaskulär- u. Ultraschalldiagnostik, Berlin, Germany

🇩🇪

Franziskus-Krankenhaus Berlin, Berlin, Germany

and more 20 locations

Reversal of the Antithrombotic Action of New Oral Anticoagulants

First Posted Date
2011-11-23
Last Posted Date
2012-03-12
Lead Sponsor
Gines Escolar
Target Recruit Count
10
Registration Number
NCT01478282
Locations
🇪🇸

Hospital Clinic, Fundació Clinic (FCRB), Barcelona, Spain

Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants

First Posted Date
2011-11-03
Last Posted Date
2017-01-24
Lead Sponsor
Janssen Scientific Affairs, LLC
Target Recruit Count
55
Registration Number
NCT01464450

Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery

First Posted Date
2011-09-09
Last Posted Date
2018-06-07
Lead Sponsor
Martini Hospital Groningen
Target Recruit Count
148
Registration Number
NCT01431456
Locations
🇳🇱

Martini Ziekenhuis, Groningen, Netherlands

A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Rivaroxaban
Drug: Warfarin
Drug: Vitamin K
First Posted Date
2011-07-22
Last Posted Date
2017-01-24
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
46
Registration Number
NCT01400646

A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)

Phase 1
Completed
Conditions
Thrombosis
Interventions
Drug: rivaroxaban
Drug: dabigatran etexilate
First Posted Date
2011-06-23
Last Posted Date
2015-10-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
42
Registration Number
NCT01379300
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy